Suppr超能文献

COVID-19 大流行对急性冠状动脉综合征结局的影响。

Impact of COVID-19 Pandemic on the Outcomes of Acute Coronary Syndrome.

机构信息

Department of Internal Medicine, University of Toledo, Toledo, OH.

Department of Internal Medicine, University of Toledo, Toledo, OH.

出版信息

Curr Probl Cardiol. 2023 Apr;48(4):101575. doi: 10.1016/j.cpcardiol.2022.101575. Epub 2022 Dec 27.

Abstract

During the pandemic, health care resources were primarily focused on treating COVID-19 infections and its related complications, with various Clinical units were converted to COVID-19 units, This study aims to investigate the impact of the COVID-19 pandemic on the clinical course of patients who had developed acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI). In this large nationwide observational study utilizing National Inpatient Sample 2019 and 2020.The primary outcomes of our study were in-hospital mortality, length of stay (LOS), total hospital charges and time from admission to percutaneous coronary intervention (PCI). Using the National Inpatient Sample 2020 database we found 32,355,827 hospitalizations in 2020 and 521,484 of which had a primary diagnosis of STEMI that met our criteria. Patients with COVID-19 infection were similar in mean age, more likely to be men, were treated in the same hospital settings as those without COVID-19 and had higher rates of diabetes with chronic complications. These patients had a similar prevalence of traditional coronary artery disease risk factors including hypertension, peripheral vascular disease and obesity. There was higher inpatient mortality (adjusted odds ratios 3.10; 95% CI, 2.40-4.02; P < 0.01) and LOS (95% CI 1.07-2.25; P < 0.01) in STEMI patient with concurrent COVID-19 infection. The average time from admission to PCI was significantly higher among unstable angina (UA) and None ST-segment elevated myocardial infarction (NSTEMI) in patients with a secondary diagnosis of COVID-19 infection compared to patients without: 0.45 days (95% CI: .155-758; P < 0.01). The COVID-19 pandemic had a significant impact on the treatment of patients with ACS, resulting in increased inpatient mortality, higher costs, and longer lengths of stay. During the pandemic, for patients with UA and NSTEMI the time from admission to PCI was significantly longer in patients with a secondary diagnosis of COVID-19 compared to patients without. When comparing ACS outcomes between pre-pandemic to pandemic periods (2019 versus 2020), the 2020 data showed higher mortality, higher hospital costs, and a decrease in LOS. Finally, the time from admission to PCI was longer for UA and NSTEMI in 2020 but not for patients with STEMI.

摘要

在大流行期间,医疗资源主要集中在治疗 COVID-19 感染及其相关并发症上,各种临床科室都被转为 COVID-19 病房。本研究旨在调查 COVID-19 大流行对已发生急性冠状动脉综合征 (ACS)(包括 ST 段抬高型心肌梗死 (STEMI))患者临床病程的影响。在这项利用 2019 年和 2020 年全国住院患者样本进行的大型全国性观察性研究中。我们的主要研究结果是院内死亡率、住院时间 (LOS)、总住院费用以及从入院到经皮冠状动脉介入治疗 (PCI) 的时间。使用 2020 年全国住院患者样本数据库,我们发现 2020 年有 32355827 例住院治疗,其中有 521484 例符合 STEMI 主要诊断标准。COVID-19 感染患者的平均年龄相似,更可能是男性,在与没有 COVID-19 的患者相同的医院环境中接受治疗,并且糖尿病伴慢性并发症的发生率更高。这些患者具有高血压、外周血管疾病和肥胖等传统冠状动脉疾病危险因素的相似患病率。COVID-19 感染合并 STEMI 的患者住院死亡率(调整后的优势比为 3.10;95%CI,2.40-4.02;P<0.01)和 LOS(95%CI,1.07-2.25;P<0.01)更高。在二级诊断为 COVID-19 感染的不稳定型心绞痛 (UA) 和非 ST 段抬高型心肌梗死 (NSTEMI) 患者中,从入院到 PCI 的平均时间明显高于无 COVID-19 感染的患者:0.45 天(95%CI:.155-758;P<0.01)。COVID-19 大流行对 ACS 患者的治疗产生了重大影响,导致住院死亡率增加、成本增加和住院时间延长。在大流行期间,对于 UA 和 NSTEMI 患者,二级诊断为 COVID-19 的患者从入院到 PCI 的时间明显长于无 COVID-19 的患者。在将 ACS 结果与大流行前(2019 年与 2020 年)进行比较时,2020 年的数据显示死亡率更高、住院费用更高,住院时间缩短。最后,UA 和 NSTEMI 的入院至 PCI 时间在 2020 年有所延长,但 STEMI 患者则没有。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dfb/9793956/f54fb56ae325/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验